Cost-utility of ferric carboxymaltose (Ferinject®) for iron-deficiency anemia patients with chronic heart failure in South Korea

Table 4 Results of the base-case and one-way sensitivity analyses (24 weeks)

Variables	Input values	Incremental costs (US $)	Incremental QALYs	ICER (US $ per QALY gained)
Base case		466	0.0210	22,192 (₩25,010,451/QALY)
Cost ratio from Berry 2001 [27]		483	0.0210	23,013
NYHA class I	0.049
NYHA class II	0.049
NYHA class III	0.120
NYHA class IV	0.831
Utilities from the mean of 2 studies based on advanced CHF patients [23, 24]		466	0.0224	20,805
NYHA class I	0.97
NYHA class II	0.8
NYHA class III	0.63
NYHA class IV	0.37
Utilities from the mean of 3 principal utility studies [22–24] ^†		466	0.0239	19,508
NYHA class I	0.95
NYHA class II	0.79
NYHA class III	0.60
NYHA class IV	0.36
FCM price ±15% (US $)	136-184	370-562	0.0210	17,630-26,754
Total number of FCM vials ± 1 vial	3-5	306-626	0.0210	14,588-29,796
CHF medical cost ± 25%	US$1,185–1,975			20,028-24,356^∮
Utilities according to NYHA class (± 10%)
NYHA class I: ± 10%	0.84-1^‡			20,485-24,954*
NYHA class II: ± 10%	0.70-0.86			17,797-29,469*
NYHA class III: ± 10%	0.55-0.67			17,945-29,073
NYHA class IV: ± 10%	0.40-0.48			21,737-22,667
Effect-onset time	sixth day	466	0.0204	22,873
Baseline CHF patient distribution from the expert survey		191	0.0547	3,496
NYHA class II	58.3%
NYHA class III	41.7%

(US $1 = Kor ₩1,127).
CHF, chronic heart failure; FMC, ferric carboxymaltose; ICER, incremental cost-effectiveness ratio; NYHA, New York Heart Association.
^†The mean of 2 results from the study of Kirsch and McGuire (2000) [21] was used.
^‡A value of 1 was applied instead of 1.023 because utility weight cannot be more than 1, although the utility weight was 1.023 in NYHA class ± 10%.
^∮As the CHF medical cost increased, the ICER decreased.
*As the utility weight increased, the ICER decreased.

ISSN: 1478-7547